首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Cancer journal

缩写:CANCER J

ISSN:1528-9117

e-ISSN:1540-336X

IF/分区:2.1/Q3

文章目录 更多期刊信息

共收录本刊相关文章索引1187条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Julie Fishman,Elizabeth I Buchbinder Julie Fishman
Immune checkpoint inhibition and targeted therapies have revolutionized the treatment of melanoma. However, chemotherapy and interleukin 2 (IL-2) therapy may still have a role in the later-line treatment of patients who do not have durable ...
Christy Los,Sebastian Klobuch,John B A G Haanen Christy Los
Major progress in prolonging survival of patients with advanced melanoma has been made in the past decade because of the development and approval of immune checkpoint inhibitor and targeted therapies. However, for nonresponding or relapsing...
Alexandra M Haugh,Adil I Daud Alexandra M Haugh
Intratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused o...
Afsaneh Amouzegar,Hussein A Tawbi Afsaneh Amouzegar
Development of brain metastasis is one of the most serious complications of advanced melanoma, carrying a significant burden of morbidity and mortality. Although advances in local treatment modalities such as stereotactic radiosurgery and b...
Mali Barbi,Richard D Carvajal,Craig E Devoe Mali Barbi
Uveal melanoma (UM), arising from intraocular melanocytes, poses a complex clinical challenge with a substantial risk of distant metastasis, often to the liver. Molecular profiling, encompassing genetic, cytogenetic, gene expression, and im...
Matthew J Hadfield,Ryan J Sullivan Matthew J Hadfield
Melanoma is the most lethal cutaneous malignancy worldwide. The last 15 years have ushered in several regulatory approvals that have dramatically altered the landscape of treatment options for patients with melanoma. Many patients with mela...
Maya Dimitrova,Jeffrey Weber Maya Dimitrova
Traditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab ove...
Madeline Miceli,Christina Boatwright,Janice M Mehnert Madeline Miceli
This review outlines the most up-to-date metastatic melanoma treatment recommendations and relevant risks for patients with solid organ transplants, patients with renal dysfunction, and patients with preexisting autoimmune conditions. These...
Ahmad A Tarhini,Ella Castellano,Islam Eljilany Ahmad A Tarhini
Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micromet...
James W Smithy,Paul B Chapman James W Smithy
The widespread adoption of immune checkpoint inhibitors and small molecule inhibitors of the MAP kinase pathway has transformed the management of locally advanced and metastatic melanoma. Here, we provide a broad overview on the use of thes...